Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

2013 
Background This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    21
    References
    142
    Citations
    NaN
    KQI
    []